Repace

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Repace

Repace: Quick Facts Overview

Property Description
Active Ingredient Losartan Potassium
Form Oral, Film-Coated Tablet
Pharmacological Class Angiotensin Receptor Blocker (ARB)
Status Prescription Only (Rx)
Typical Use Management of chronic cardiovascular conditions.

What Type of Medicine Is Repace?

Repace is a synthetic small molecule drug primarily containing Losartan Potassium, which places it in the pharmacological class of Angiotensin Receptor Blockers (ARBs). As a prescription-only (Rx) medication, its use requires professional oversight for proper management of complex, long-term conditions.

Losartan is clinically recognized for its high selectivity for the AT1 receptor, a key factor in cardiovascular regulation. This focused action helps to differentiate the ARB class from older, less selective agents. Losartan's structure allows it to target specific processes involved in blood flow.


What is Repace's Active Ingredient and Origin?

The effect of Repace comes from its single active compound, Losartan, which is combined with potassium for optimal stability and absorption. This non-peptide compound is entirely synthetically manufactured through controlled chemical processes to ensure precise purity and consistency.

Losartan acts as an antagonist of the Angiotensin II receptor, meaning it blocks the effects of a naturally occurring chemical that causes blood vessels to narrow. The chemical structure of Losartan is designed for this selective blocking function. The core therapeutic purpose is tied to promoting smoother circulatory flow.


What is the Physical Form of Repace?

Repace is consistently supplied as an oral, film-coated tablet. This solid dosage form is designed for convenient, non-invasive administration, which is highly suitable for medicines requiring long-term, routine daily intake.

The film coating and oral route are strategic choices in its formulation. This tablet form is optimized for stability and to ensure that the Losartan compound is efficiently absorbed into the bloodstream. This consistent delivery is vital for maintaining the stable therapeutic effect required for the management of chronic conditions.

Regulatory References

  1. NIH

What side effects are possible with Repace?

Possible side effects and safety information

The official safety profile for Losartan Potassium (Repace) is organized by regulatory agencies, classifying potential adverse reactions by frequency and physiological system. All documented safety information is derived strictly from government regulatory sources.


Adverse Reaction Scope

The most common adverse reactions (ge 1% to < 10%) listed in official documents generally include dizziness, upper respiratory infection, and back pain. These effects are categorized across system-organ classes such as Nervous System Disorders, Respiratory Disorders, and Musculoskeletal Disorders. Uncommon and rare effects are also documented, with rare events including serious hypersensitivity reactions like angioedema.


Serious Adverse Reactions and Safety Constraints

The label includes critical warnings concerning fetal toxicity, which is associated with use during pregnancy and can result in injury or death to the fetus, leading to a strict contraindication for pregnant individuals. The risk of severe hypotension and renal function deterioration is also documented, particularly in susceptible populations.

Population-Specific Constraints are explicitly noted: use is not recommended in pediatric patients with severe renal impairment (eGFR below 30 mL/min/1.73 m^2). Furthermore, a specific safety pattern notes that hypotension or dizziness is often more likely at the initiation of treatment or following a dose adjustment. High-level safety restrictions also contraindicate use with Aliskiren in patients with diabetes mellitus, and advise caution for patients with conditions like severe congestive heart failure.

Overdose and Emergency Response

The official regulatory profile for Repace (Losartan Potassium) overdose describes the manifestations expected from an exaggeration of the drug’s primary effect. The most likely clinical consequence is symptomatic hypotension, characterized by abnormally low blood pressure, which may present with dizziness or fainting. Other documented signs involve the cardiovascular system, including changes in heart rate such as tachycardia or, less frequently, bradycardia.

Overdose carries the risk of serious organ-specific outcomes. Regulatory documents note the potential for acute kidney injury (renal function deterioration) and dangerous levels of hyperkalemia (elevated serum potassium), particularly in patients with pre-existing renal or hepatic impairment.

Immediate emergency medical intervention is mandated if an overdose is suspected. Government labeling instructs individuals to seek emergency medical attention immediately and contact a medical professional or hospital.

Management for an overdose is exclusively symptomatic and supportive. This approach is necessary because regulatory information confirms that Losartan and its active metabolite cannot be removed effectively by hemodialysis. Therefore, management involves close observation, stabilization of blood pressure, and monitoring of key physiological parameters like serum electrolytes.

Therapeutic Uses of Repace

What Repace Treats: Main Uses and Benefits

Repace is commonly used in the management of Chronic Hypertension, a condition marked by increased physiological stress from persistently elevated blood pressure. It is applied in addressing conditions like high blood pressure, Chronic Heart Failure, and Diabetic Nephropathy. Its primary benefit is to deliver sustained blood pressure reduction, which generally may assist with protecting the cardiovascular system from conditions linked to organ-specific functional stress.

The medication is considered relevant in managing progressive consequences related to high pressure, such as Left Ventricular Hypertrophy (LVH). By addressing this strain, the medicine may assist with reducing the risk of major cardiovascular events, including stroke and heart attack, contributing to long-term stability for patients with established hypertensive conditions.

For diabetic patients, Repace is relevant for managing symptoms that interfere with daily comfort, such as protein leakage in the urine (proteinuria). It assists with maintaining functional stability and supports the management of conditions where functional stability becomes affected, helping to ease the overall symptom load.

“The medication's role is to provide continuous, long-term support to help patients cope more steadily with symptom fluctuations associated with chronic cardiovascular issues.”

Quick Fact: Support for Chronic Conditions
Symptom Domain Key Benefit
Systemic high blood pressure Contributes to easing the overall symptom load and helps maintain functional stability.
Kidney stress in diabetes Supports patients during episodes of heightened discomfort by managing specific symptomatic manifestations.

Regulatory References

  1. NIH DailyMed Label

Eligibility and Restrictions for Use

Repace’s regulatory eligibility profile strictly defines which patient populations are permitted, restricted, or prohibited from using the medicine. This is governed by official government-approved labeling (e.g., FDA Prescribing Information and EMA Summary of Product Characteristics).

Contraindications (Must NOT Use)

Category Official Regulatory Status
Hypersensitivity Patients with a known serious hypersensitivity reaction to the active substance or any component.
Absolute Conditions Use is contraindicated in specific, severe underlying conditions, such as severe, end-stage hepatic impairment, as stated in the label.

Special Populations and Restrictions

Category Official Regulatory Status
Age-Related Use is not established or not approved in pediatric patients younger than the minimum age specified in the label. Geriatric use often requires special consideration but is not typically prohibited by age alone.
Organ Function Use is restricted or requires special caution in patients with moderate impairment of key organs (e.g., kidney or liver) that affects drug clearance.
Pregnancy/Lactation Use is generally not recommended or restricted during pregnancy and lactation due to potential risks, as documented in the product's risk summaries.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the documented interaction patterns for Losartan (Repace) as classified and described in governmental regulatory sources. The official interaction profile is structured around contraindicated combinations, pharmacodynamic risk, and pharmacokinetic changes.

Official Interaction Statements

  • Co-administration with Aliskiren is formally contraindicated in patients with a history of diabetes or renal impairment (kidney disease). This restriction is due to an increased risk of severe hypotension, hyperkalemia, and worsening renal function.
  • Co-administration with Potassium-sparing diuretics (e.g., spironolactone), Potassium supplements, or salt substitutes carries a risk of additive effects, potentially leading to hyperkalemia (high serum potassium).
  • The combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, increases the risk of deterioration in renal function and may reduce the drug's antihypertensive effect.
  • The use of the CYP2C9 inhibitor Fluconazole significantly increases the Losartan plasma concentration while decreasing the exposure of its active metabolite, representing a documented pharmacokinetic interaction.
  • Medicines that induce CYP enzymes, such as Rifampin and Phenobarbital, decrease the overall systemic exposure (AUC) of both Losartan and its active metabolite.
  • Administration with food is documented to slow the rate of absorption and result in a minor, approximately 10%, reduction in the total overall exposure (AUC).

Mechanism of Action

How Repace Works

The mechanism of Repace (Losartan) is defined by its highly specific action within the hormonal signaling network that regulates blood vessel tension and fluid balance.


Molecular Blockade of Angiotensin II Signaling

Repace's active metabolite ( E-3174) acts as a selective antagonist to the Angiotensin II Type 1 ( AT1) receptor. This molecular blockade interrupts the vasoconstrictive signals normally transmitted by the hormone Angiotensin II, initiating a cascade that leads to the relaxation of vascular smooth muscle.


Modulation of the RAAS Cascade and Fluid Excretion

By disrupting the Angiotensin II signal, the drug modulates the entire Renin-Angiotensin-Aldosterone System (RAAS). This suppression results in decreased release of Aldosterone, which in turn reduces the kidney's retention of sodium and water. This adjustment in fluid and electrolyte handling leads to reduced circulating fluid volume and decreased mechanical tension within the circulatory system.


Reduction of Signaling Related to Tissue Remodeling

Beyond its immediate effects on tone and volume, the sustained blockade of AT1 signaling suppresses the chronic, abnormal growth and inflammatory signals that Angiotensin II exerts on the heart and vessel walls. This targeted action reduces the signals that promote pathological tissue changes (hypertrophy and fibrosis) in the heart and vessel walls.

Dosage and Administration Information

How Repace is Used

Repace (Losartan Potassium) is an oral medication administered according to specific schedules for the management of chronic cardiovascular conditions. The established protocols provide a structured pattern for initiating and adjusting therapy.


Official Administration Guidelines

Feature Guideline
Route of Administration Oral. The standard form is the film-coated tablet.
Dosing Frequency Typically prescribed to be taken once daily.
Food Relationship May be taken either with or without food.
Tablet Intake Tablets should be swallowed whole with water, not crushed or chewed.

Standard Dosing Regimens and Adjustments

The most common initial dose for adults is 50 mg once daily. However, for patients who may have a low volume status or pre-existing hepatic impairment, a lower starting dose of 25 mg once daily is generally used.

Adult Dosing Range Guideline
Initial Dose (Standard) 50 mg once daily.
Maximum Daily Dose 100 mg once daily.
Dose Titration Adjustments to a higher dose are typically evaluated and performed 3 to 6 weeks after the start of therapy.

Population-Specific Rules

Losartan use includes specific rules for certain populations. For pediatric patients aged 6 years and older, the initial dose is calculated by weight at 0.7 mg/kg once daily, up to a maximum of 50 mg total daily dose. A low starting dose of 25 mg is required for patients with mild-to-moderate hepatic impairment. If a daily dose is missed, patients are directed to take the next scheduled dose at the usual time and are instructed not to take a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Repace

The research available for Repace (Losartan Potassium) comes primarily from large-scale Randomized Controlled Trials (RCTs) and peer-reviewed systematic reviews. This body of evidence describes patterns observed in specific patient groups, focusing on measurable physiological changes and monitoring the occurrence of specific clinical events over set periods. This overview summarizes what types of research have been conducted for each major condition, what the general findings indicate, and where the scientific evidence remains limited or unclear.


Evidence Base for Chronic Hypertension

The research base for managing high blood pressure involves numerous short-term RCTs. Studies described patterns where measured changes in blood pressure were tracked between the Losartan groups and the placebo groups during these short-term periods. Research explored different daily amounts, with data showing patterns where the effects of additional increases in the amount above a certain level were not proportionally tracked in the measured blood pressure. What is still uncertain is the long-term stability and durability of these measured changes, as primary controlled trials often had limited follow-up durations.


Research on Reducing the Risk of Stroke and LVH Complications

For patients with hypertension and Left Ventricular Hypertrophy (LVH), Repace was evaluated in large-scale, long-term Outcome Trials. These studies monitored outcomes by tracking major clinical events, including the first occurrence of stroke, non-fatal heart attack, or cardiovascular death. The findings described related to the stroke outcome in hypertensive patients with LVH were not tracked in the specific cohort of Black patients included in the main outcome trial. The research describes group patterns, and findings cannot predict whether individual outcomes will be similar for all patients.


Studies in Type 2 Diabetes with Kidney Complications

Research for diabetic nephropathy explored outcomes related to systemic or functional imbalance by monitoring a composite endpoint that was defined to track severe kidney events, such as the need for dialysis. Findings describe patterns observed where the frequency of reaching the severe composite kidney endpoint was tracked in the Losartan group compared to the placebo group. The trials did not report consistent patterns related to the composite outcome of other major cardiovascular events, indicating certainty remains low regarding its association with other major cardiovascular events in these patients.

Frequently Asked Questions (FAQ)

Common questions about Repace (FAQ)


Q: Is Repace considered a long-term medication or is its use typically short-term?

A: Repace, containing Losartan, is generally intended for the long-term management of chronic cardiovascular conditions. Official product information emphasizes the medication's use for sustained control of chronic conditions.


Q: Can Repace be used by patients with a history of kidney disease?

A: Official information indicates that no initial dosage adjustment is typically necessary for patients with renal (kidney) impairment, including those on dialysis. However, regulatory guidance advises that a patient’s kidney function requires monitoring throughout treatment.


Q: Does Repace need to be taken at the exact same time every day for it to work?

A: The medication is typically prescribed to be taken once daily. A consistent daily routine is generally favored for chronic, once-daily medications to ensure stable levels of the drug in the body.


Q: Is Repace a controlled substance or is it non-scheduled?

A: Losartan, the active ingredient in Repace, is not listed as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This classification indicates that it is not considered a drug with a high potential for abuse or dependence.


Q: Can Repace cause rebound symptoms if it is stopped abruptly?

A: Studies and clinical data indicate that rebound hypertension (a sudden, significant increase in blood pressure) has not been reported following the abrupt discontinuation of Losartan. This suggests that withdrawal symptoms are not typically documented upon cessation of the medication.


Q: Is Repace generally recommended for pregnant or breastfeeding women?

A: The use of Repace is strongly avoided during pregnancy, especially in the second and third trimesters, due to the documented risk of severe injury or death to the fetus. Regulatory documents mention the need for patients to discuss their breastfeeding status with a healthcare provider.


Q: What are the signs of a rare but serious adverse reaction to Repace?

A: A documented, rare but serious adverse reaction is angioedema, which is rapid swelling. Documented signs of this reaction include swelling of the face, tongue, throat, lips, eyes, hands, or lower legs, as well as difficulty breathing or swallowing.


Q: Is it generally known if Repace interacts with grapefruit or grapefruit juice?

A: Yes, interaction information states that the consumption of grapefruit or grapefruit juice may potentially decrease the efficacy of Losartan in some patients.


Q: Are there any known effects of Repace on mood or sleep patterns?

A: Adverse event reporting includes potential effects on sleep. Insomnia (difficulty sleeping) is documented as a common side effect, and sleep disorder is listed as an uncommon adverse effect in regulatory data.


Q: Does Repace have any documented effects on hair loss or skin changes?

A: Yes, adverse event reporting includes some dermatologic effects. The regulatory data lists alopecia (hair loss) and photosensitivity (increased sensitivity to sunlight) under the potential side effects category.


Q: What is the interaction risk between Repace and alcohol consumption?

A: Official information indicates that Repace and alcohol may have additive effects in lowering blood pressure (hypotension). This effect may result in symptoms such as dizziness, lightheadedness, or fainting.


Q: Is Repace described as safe for use in elderly patients (over 65)?

A: The regulatory information states that no initial dosage adjustment is typically necessary for elderly patients when starting Losartan therapy. Use in geriatric populations is a matter that requires special consideration and monitoring.


Q: How long does it usually take to feel the full effects of Repace?

A: For the management of high blood pressure, the maximal antihypertensive effect is typically attained 3 to 6 weeks after the start of therapy. This indicates that the full effect on blood pressure develops gradually.


Q: How soon after starting Repace might a patient notice a change in their condition?

A: While the full effect takes several weeks, official information suggests that blood pressure may begin to decrease during the first week of treatment.


Q: Is Repace approved by [Foreign regulatory body, e.g., EMA] or only by the FDA?

A: The active compound, Losartan, has been approved by the US FDA and also holds European marketing authorizations. This means the drug is regulated and approved for use across multiple major jurisdictions.


Q: What is the process for reporting an adverse event related to Repace to the authorities?

A: Adverse events or quality problems are reported to the US FDA's MedWatch Adverse Event Reporting program. Reports can be submitted online, by regular mail, or by fax.


Q: Is Repace known to cause a false positive result on any type of medical test?

A: Available clinical evidence suggests that Losartan is not associated with causing false-positive results on standard urine drug screening tests due to cross-reactivity with the testing assays.


Q: Is Repace considered to be an addictive medication?

A: The drug is not considered a drug of abuse by regulatory organizations, and official records show that it is not listed as a controlled substance by the DEA.


Q: Do studies suggest Repace has any effect on sexual function?

A: Adverse event reporting includes effects on sexual function. Loss in sexual ability, desire, drive, or performance has been reported as a possible, but rare, adverse effect in clinical data.


Q: What evidence is available on stopping Repace and the potential for withdrawal symptoms?

A: Clinical data do not suggest a need for tapering the dose before stopping and report that rebound hypertension or withdrawal symptoms are not documented with discontinuation.


Q: Is there a maximum duration of therapy officially suggested for Repace?

A: Repace is prescribed for the long-term management of chronic conditions. Regulatory documents do not specify a maximum duration of therapy for its approved uses.


Q: What are the known effects of Repace on blood pressure?

A: Repace is a medication used to lower blood pressure by blocking the action of substances (Angiotensin II) that cause blood vessels to narrow. This action allows blood to flow more smoothly through the circulatory system.


Q: What information exists about the half-life of Repace in the body?

A: Official pharmacokinetic data indicates that Repace and its active components have different half-lives. The terminal half-life of Losartan itself is approximately 2 hours, and the half-life of its active metabolite is approximately 6 to 9 hours.


Q: How quickly do side effects from Repace typically start or stop?

A: Side effects such as dizziness or low blood pressure (hypotension) are generally most likely to occur at the initiation of treatment or immediately following a dose adjustment.


Q: What is Repace's Active Ingredient and Origin?

A: The active ingredient in Repace is Losartan Potassium, which is identified as a synthetic small molecule drug. This means it is produced through controlled chemical processes.


Q: Can Repace be taken by people who are lactose intolerant?

A: Official regulatory labels indicate that the inactive ingredients section lists lactose monohydrate as an ingredient in the film-coated tablet formulation. The presence of this ingredient means the medication may not be suitable for individuals with lactose intolerance.

How should Repace be stored and disposed of?

The storage and disposal of Repace (Losartan Potassium) must strictly follow the conditions defined in the official regulatory documents to maintain drug stability.

Official Storage Requirements

Losartan tablets must be stored at Controlled Room Temperature, typically defined as not exceeding 30 C. It is mandatory to keep the tablets in their original container and ensure it is tightly closed to protect the active ingredient from light and excessive moisture. The product should not be frozen.

Child-Safety and Disposal

All Repace tablets must be stored out of the reach and sight of children to prevent accidental ingestion. For disposal of unused or expired medicine, regulatory agencies strongly recommend utilizing an authorized drug take-back program or consulting a pharmacist. This is because the medicine should not be disposed of via wastewater or household trash (sewers or drains) to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Repace found in:

A-Z Index: